Journal Guides8 min readUpdated Mar 25, 2026

JAMA Oncology Acceptance Rate

JAMA Oncology does not publish a strong official acceptance rate. The better submission question is whether the study delivers practice-changing clinical oncology evidence at a population level.

Senior Researcher, Oncology & Cell Biology

Author context

Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.

Journal evaluation

Want the full journal picture?

See scope, selectivity, submission context, and what editors actually want before you decide whether the journal is realistic.

Open Journal GuideAnthropic Privacy Partner. Zero-retention manuscript processing.Run Free Readiness Scan

Quick answer: there is no strong official JAMA Oncology acceptance-rate number you should treat as exact. Third-party estimates place it in the 8–13% range, with a reported median time to first decision of about 21 days. With a 2025 JCR impact factor of ~20.1, JAMA Oncology is among the most selective oncology journals — but the editorial bar is about practice-changing clinical evidence, not just study quality.

If the paper is a small translational study without clear clinical implications, the acceptance-rate estimates are not the real constraint. The clinical impact is.

What you can say honestly about the acceptance rate

The AMA does not publish a stable official acceptance rate for JAMA Oncology. Third-party aggregators report estimates in the 8–13% range. These are directionally useful — this is clearly a very selective oncology journal — but the exact figure varies by source and year.

What is more stable is the editorial context:

  • JAMA Oncology is part of the JAMA Network, with the JAMA editorial standards and review process
  • the journal publishes monthly and emphasizes clinical oncology with population-level evidence
  • median time to first decision is reported around 21 days, which is fast for this tier
  • clinical trials, meta-analyses, and large registry studies are prioritized

That clinical-evidence focus and JAMA-network editorial rigor define the real submission bar.

What the journal is really screening for

At triage, the editor is usually asking:

  • does this study change how oncologists will treat, screen, or monitor cancer patients?
  • is the evidence clinical-level — randomized trials, large cohorts, systematic reviews, or registry analyses?
  • does the study design meet JAMA Network standards for statistical rigor and reporting?
  • would the findings inform clinical guidelines or oncology practice?

Papers with large, well-designed clinical trials or population-level evidence will survive triage at much higher rates than small translational studies or single-center observations.

The better decision question

For JAMA Oncology, the useful question is:

Does this study provide clinical oncology evidence strong enough to change practice or inform guidelines?

If yes, the journal is a strong fit. If the paper is primarily translational, primarily basic science, or a small clinical study without population-level implications, the acceptance rate is not the constraint. The clinical evidence level is.

Where authors usually get this wrong

The common misses are:

  • centering strategy around an estimated percentage instead of checking clinical evidence level
  • submitting translational work without a strong clinical bridge (better suited for CCR or Cancer Research)
  • presenting single-center data without population-level generalizability
  • underestimating JAMA Network reporting and statistical standards
  • ignoring JCO as the primary competitor for the same manuscript pool

Those are evidence-level and scope problems before they are rate problems.

What to use instead of a guessed percentage

If you are deciding whether to submit, these pages are more useful than an estimated rate:

Together, they tell you whether the paper has enough clinical weight, whether the editorial timeline is manageable, and whether a different clinical oncology venue would be a cleaner fit.

Practical verdict

The honest answer to "what is the JAMA Oncology acceptance rate?" is that the AMA does not publish one, and third-party estimates in the 8–13% range should be treated as approximate.

The useful answer is:

  • yes, this is among the most selective oncology journals
  • the ~21-day median decision time is well-documented and fast for this tier
  • use practice-changing evidence, clinical-trial data, and JAMA reporting standards as the real filter instead

If you want help pressure-testing whether this manuscript meets the clinical evidence bar before upload, a free Manusights scan is the best next step.

References

Sources

  1. 1. JAMA Oncology, AMA/JAMA Network.
  2. 2. JAMA Oncology author instructions, JAMA Network.
  3. 3. Clarivate Journal Citation Reports, 2025 edition (IF ~20.1).
  4. 4. SCImago Journal & Country Rank: JAMA Oncology, Q1 ranking.

Reference library

Use the core publishing datasets alongside this guide

This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.

Open the reference library

Before you upload

Want the full journal picture?

Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.

These pages attract evaluation intent more than upload-ready intent.

Anthropic Privacy Partner. Zero-retention manuscript processing.

Internal navigation

Where to go next

Open Journal Guide